Preoperative low skeletal muscle volume can result in insufficient administration of S-1 adjuvant chemotherapy in older patients with stage II/III gastric cancer

被引:1
|
作者
Kono, Yusuke [1 ]
Matsunaga, Tomoyuki [1 ]
Makinoya, Masahiro [1 ]
Shimizu, Shota [1 ]
Shishido, Yuji [1 ]
Miyatani, Kozo [1 ]
Kihara, Kyoichi [1 ]
Yamamoto, Manabu [1 ]
Takano, Shuichi [1 ]
Tokuyasu, Naruo [1 ]
Sakamoto, Teruhisa [1 ]
Hasegawa, Toshimichi [1 ]
Fujiwara, Yoshiyuki [1 ]
机构
[1] Tottori Univ, Sch Med, Dept Surg, Div Surg Oncol,Fac Med, 36-1 Nishi Cho, Yonago 6838504, Japan
关键词
Gastric cancer; Adjuvant chemotherapy; Sarcopenia; Elderly; S-1; ANAMORELIN;
D O I
10.1007/s00595-023-02737-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and purposeOlder patients are more likely to encounter difficulties receiving chemotherapy, but the factors involved in the continuation of chemotherapy in these patients remain unclear. We investigated the importance of muscle mass as a factor involved in delivering a sufficient dose of postoperative S-1 adjuvant chemotherapy (ACT) to older patients with gastric cancer.MethodsThe subjects of this study were 79 patients aged & GE; 65 years with stage II/III gastric adenocarcinoma, who underwent curative gastrectomy and received S-1 ACT.ResultsThe overall median relative dose intensity (RDI) was 75.0% (18.8-93.5%). Patients were divided into two groups for receiver operating characteristic analysis according to the cutoff value. Significantly more patients in the high skeletal muscle index (SMI) group achieved > 62% RDI of S-1 ACT (p = 0.03). Conversely, more patients in the low SMI group suffered from S-1-induced nausea (p = 0.03) and discontinued chemotherapy because of adverse events (p = 0.02). Multivariate analysis identified low SMI as an independent factor for insufficient S-1 dose delivery (p = 0.03, hazard ratio = 2.87).ConclusionPreoperative SMI is an indicator of the low-dose intensity of S-1 ACT in older patients following curative gastrectomy.
引用
收藏
页码:340 / 346
页数:7
相关论文
共 50 条
  • [41] Comparison of 2-and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer
    Ogawa, Koichi
    Honda, Michitaka
    Akashi, Yoshimasa
    Inagawa, Satoshi
    Kaneda, Akinao
    Hori, Soshi
    Owada, Yohei
    Ohara, Yusuke
    Hisakura, Katsuji
    Enomoto, Tsuyoshi
    Shimomura, Osamu
    Takahashi, Kazuhiro
    Oda, Tatsuya
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (10) : 1807 - 1813
  • [42] Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1
    Koji Numata
    Takashi Oshima
    Kentaro Sakamaki
    Kazue Yoshihara
    Toru Aoyama
    Tsutomu Hayashi
    Takanobu Yamada
    Tsutomu Sato
    Haruhiko Cho
    Manabu Shiozawa
    Takaki Yoshikawa
    Yasushi Rino
    Chikara Kunisaki
    Makoto Akaike
    Toshio Imada
    Munetaka Masuda
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 415 - 422
  • [43] Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1
    Numata, Koji
    Oshima, Takashi
    Sakamaki, Kentaro
    Yoshihara, Kazue
    Aoyama, Toru
    Hayashi, Tsutomu
    Yamada, Takanobu
    Sato, Tsutomu
    Cho, Haruhiko
    Shiozawa, Manabu
    Yoshikawa, Takaki
    Rino, Yasushi
    Kunisaki, Chikara
    Akaike, Makoto
    Imada, Toshio
    Masuda, Munetaka
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (02) : 415 - 422
  • [44] Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer
    Koichi Ogawa
    Michitaka Honda
    Yoshimasa Akashi
    Satoshi Inagawa
    Akinao Kaneda
    Soshi Hori
    Yohei Owada
    Yusuke Ohara
    Katsuji Hisakura
    Tsuyoshi Enomoto
    Osamu Shimomura
    Kazuhiro Takahashi
    Tatsuya Oda
    International Journal of Clinical Oncology, 2020, 25 : 1807 - 1813
  • [45] Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer
    Wataru Ichikawa
    Masanori Terashima
    Atsushi Ochiai
    Koji Kitada
    Issei Kurahashi
    Shinichi Sakuramoto
    Hitoshi Katai
    Takeshi Sano
    Hiroshi Imamura
    Mitsuru Sasako
    Gastric Cancer, 2017, 20 : 263 - 273
  • [46] Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer
    Ichikawa, Wataru
    Terashima, Masanori
    Ochiai, Atsushi
    Kitada, Koji
    Kurahashi, Issei
    Sakuramoto, Shinichi
    Katai, Hitoshi
    Sano, Takeshi
    Imamura, Hiroshi
    Sasako, Mitsuru
    GASTRIC CANCER, 2017, 20 (02) : 263 - 273
  • [47] Different risk factors for three major recurrence patterns of pathological stage II or III gastric cancer patients who completed adjuvant S-1 monotherapy
    Kano, Yosuke
    Ohashi, Manabu
    Muneoka, Yusuke
    Takahari, Daisuke
    Chin, Keisho
    Yamaguchi, Kensei
    Ida, Satoshi
    Kumagai, Koshi
    Makuuchi, Rie
    Sano, Takeshi
    Nunobe, Souya
    EJSO, 2021, 47 (12): : 3097 - 3104
  • [48] Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer
    Takashi Kosaka
    Hirotoshi Akiyama
    Hirochika Makino
    Ryo Takagawa
    Jun Kimura
    Hidetaka Ono
    Chikara Kunisaki
    Itaru Endo
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 281 - 285
  • [49] Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy
    Tamura, Shigeyuki
    Fujitani, Kazumasa
    Kimura, Yutaka
    Tsuji, Takeshi
    Matsuyama, Jin
    Iijima, Shohei
    Imamura, Hiroshi
    Inoue, Kentaro
    Kobayashi, Kenji
    Kurokawa, Yukinori
    Furukawa, Hiroshi
    ONCOLOGY, 2011, 80 (5-6) : 296 - 300
  • [50] Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer
    Eiji Oki
    Yasunori Emi
    Tetsuya Kusumoto
    Yoshihisa Sakaguchi
    Manabu Yamamoto
    Noriaki Sadanaga
    Mototsugu Shimokawa
    Takeharu Yamanaka
    Hiroshi Saeki
    Masaru Morita
    Ikuo Takahashi
    Naoki Hirabayashi
    Kenji Sakai
    Hiroyuki Orita
    Shinichi Aishima
    Yoshihiro Kakeji
    Kazuya Yamaguchi
    Kazuhiro Yoshida
    Hideo Baba
    Yoshihiko Maehara
    Annals of Surgical Oncology, 2014, 21 : 2340 - 2346